Ajanta Pharmaceuticals Ltd.

NSE: AJANTPHARM · Healthcare

₹3,307.70+0.78%06 Nov 2026

Ask the data

Instant answers about Ajanta Pharmaceuticals Ltd. — computed from its filings, no language model

Market cap₹41,462 cr

Current price₹3,307.70

High / Low₹3,718 / ₹2,458

P/E32.9

P/B8.53

Book value₹387.6

ROE25.9%

ROCE34.3%

Debt / equity0.02

Dividend yield0.84%

EPS (TTM)₹100.40

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	2,131	2,055	2,588	2,890	3,341	3,743	4,209	4,648	5,453
EBITDA	658	566	683	999	929	783	1,172	1,260	1,395
Operating margin	30.9%	27.6%	26.4%	34.6%	27.8%	20.9%	27.8%	27.1%	25.6%
Interest	0	1	12	8	10	6	7	21	16
Depreciation	60	72	96	116	125	131	135	144	173
Profit before tax	623	514	664	900	909	745	1,114	1,189	1,378
Tax	154	127	196	246	197	157	298	269	322
Net profit	472	384	468	654	0	0	817	920	1,056
EPS ₹	53.26	43.97	53.60	75.09	82.45	45.89	64.82	73.56	84.53
Operating cash flow	—	—	—	—	562	792	785	1,157	529
Capex	—	—	—	—	149	174	152	318	365
Dividend paid	—	—	—	—	82	90	642	349	350
Total assets	2,449	2,696	3,319	3,779	4,056	4,679	4,638	5,015	6,155
Equity	2,041	2,245	2,599	2,996	3,264	3,388	3,567	3,790	4,527

Quarterly performance

last 34 quarters · ₹ crore

showing latest 8 of 34 periods

	MAR '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	530	544	485	515	612	643	651	682	668	716	749	757	748	885	838	870	951	938	972	882	1,021	1,028	1,105	1,054	1,145	1,187	1,146	1,170	1,303	1,354	1,375	1,422	1,626	1,794
Operating profit	140	166	107	127	168	178	186	151	223	274	242	259	220	263	240	207	222	196	170	149	271	291	314	278	330	311	321	297	351	328	382	333	424	548
Operating margin	26.3%	30.5%	22.1%	24.7%	27.5%	27.6%	28.6%	22.2%	33.4%	38.3%	32.3%	34.3%	29.4%	29.7%	28.6%	23.7%	23.3%	20.9%	17.4%	16.9%	26.6%	28.3%	28.4%	26.4%	28.9%	26.2%	28.0%	25.4%	27.0%	24.2%	27.8%	23.5%	26.1%	30.5%
Other income	5	15	4	2	8	13	15	57	13	5	5	3	33	30	24	29	33	40	35	37	32	21	14	36	26	19	30	18	26	59	25	61	71	37
Interest	0	0	0	1	2	5	2	4	2	2	3	3	2	0	1	7	1	1	3	1	1	2	2	2	1	6	8	6	5	3	5	2	3	2
Depreciation	17	17	19	19	23	23	24	26	28	28	29	31	31	32	32	31	32	33	33	33	33	34	34	34	34	34	36	40	41	43	44	45	44	48
Profit before tax	128	164	93	109	151	162	175	176	207	249	215	229	220	260	231	198	222	203	168	152	269	276	291	278	322	290	307	269	331	341	359	347	447	535
Tax	34	38	26	20	37	45	68	47	59	79	39	70	47	64	39	46	47	46	34	30	61	81	81	75	76	74	75	44	76	81	85	80	113	147
Net profit	95	125	0	89	113	116	108	129	148	170	176	159	174	0	0	0	0	0	0	0	0	0	0	196	238	216	233	225	255	260	274	267	330	388
EPS ₹	10.74	14.25	7.60	10.10	13.14	13.34	12.33	14.80	16.93	19.51	20.41	18.40	20.08	22.64	22.16	17.70	13.63	12.22	10.50	9.54	16.53	15.51	16.68	16.10	19.54	17.27	18.60	18.00	20.44	20.83	21.91	21.35	26.75	31.07
Revenue YoY	—	—	—	-2.9%	—	18.1%	34.2%	32.4%	9.2%	11.4%	15.0%	11.0%	11.9%	23.6%	11.9%	15.0%	27.1%	6.0%	16.0%	1.3%	7.4%	9.6%	13.7%	19.5%	12.1%	15.4%	3.7%	11.0%	13.8%	14.1%	20.0%	21.5%	24.8%	32.5%
Profit YoY	—	—	—	-7.0%	—	-7.2%	—	45.4%	30.4%	46.3%	63.8%	23.3%	17.6%	-100.0%	-100.0%	-100.0%	-100.0%	—	—	—	—	—	—	—	—	—	—	14.7%	7.1%	20.2%	17.6%	18.4%	29.2%	49.2%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Ajanta Pharmaceuticals Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	321	382	457	602	839	1,111	1,356	1,552	1,818
Operating profit	61	71	90	118	209	343	473	516	629
Operating margin	19.0%	18.7%	19.6%	19.6%	24.9%	30.9%	34.8%	33.2%	34.6%
Other income	—	1	2	1	17	20	34	82	74
Interest	22	19	16	12	29	8	5	4	3
Depreciation	13	20	24	31	33	42	49	43	59
Profit before tax	26	34	52	80	164	313	445	551	641
Tax	5	5	5	13	62	92	139	137	141
Net profit	21	29	46	66	101	221	306	414	500

Quarters

showing latest 8 of 42 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	70	71	87	69	87	75	89	85	95	95	108	98	113	120	126	127	135	164	176	174	186	229	249	219	280	301	311	287	337	363	369	341	390	420	402	413	478	509	418	398	469	501
Operating profit	10	11	17	13	15	15	19	15	18	17	21	18	21	23	28	21	23	34	40	37	43	60	68	51	84	97	111	90	111	131	141	110	128	149	129	143	169	176	142	110	157	154
Operating margin	14.4%	15.5%	19.1%	18.4%	16.8%	19.4%	21.3%	18.2%	18.5%	18.4%	19.4%	18.2%	18.6%	18.9%	22.2%	16.7%	17.2%	20.6%	22.6%	21.3%	23.2%	26.1%	27.4%	23.3%	30.1%	32.3%	35.5%	31.2%	32.8%	36.2%	38.2%	32.2%	32.7%	35.5%	32.2%	34.6%	35.4%	34.5%	33.9%	27.7%	33.6%	30.7%
Other income	0	0	0	0	—	—	0	0	0	0	1	0	0	1	0	2	0	1	-2	10	0	0	6	7	6	4	3	9	16	6	3	14	23	4	42	8	7	51	7	5	8	65
Interest	3	4	5	5	6	5	6	5	6	4	4	4	4	3	4	3	3	4	2	16	5	3	5	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0
Depreciation	2	2	2	3	3	3	4	4	4	5	6	5	6	6	7	7	8	8	8	8	8	8	9	9	9	9	15	12	12	13	13	10	10	11	12	12	13	15	19	13	14	14
Profit before tax	5	6	11	5	6	6	9	6	7	9	12	9	11	14	18	14	12	22	31	23	31	49	60	48	79	90	96	85	113	124	123	113	139	141	158	138	162	211	130	102	151	204
Tax	2	2	2	2	2	1	0	2	1	1	2	2	1	2	1	1	1	4	8	4	9	16	33	15	23	27	26	26	34	39	39	32	45	38	23	38	41	40	22	25	44	39
Net profit	3	4	9	3	4	5	9	4	6	8	10	7	10	12	17	13	12	19	24	20	22	33	27	33	56	62	70	59	79	85	84	81	94	103	136	100	121	171	108	77	108	165
EPS ₹	2.40	3.37	7.47	2.69	3.69	3.93	7.95	3.74	5.49	6.57	8.58	5.96	8.58	10.21	14.92	10.70	10.12	15.81	20.15	16.72	9.34	13.91	11.56	13.89	15.88	17.75	19.94	16.70	22.35	24.08	9.59	9.21	10.73	11.74	15.42	11.35	13.75	19.42	12.27	8.72	12.24	18.70
Revenue YoY	—	—	—	—	24.2%	6.1%	2.9%	22.1%	8.5%	26.5%	20.7%	16.3%	18.9%	27.3%	16.6%	29.5%	20.1%	36.0%	39.9%	36.7%	37.9%	39.9%	41.6%	25.8%	50.1%	31.2%	24.7%	31.3%	20.5%	20.5%	18.6%	18.5%	15.5%	15.8%	8.9%	21.3%	22.7%	21.1%	4.2%	-3.6%	-1.8%	-1.5%
Profit YoY	—	—	—	—	53.7%	16.8%	6.4%	38.7%	48.8%	67.2%	7.8%	59.7%	56.3%	55.4%	74.0%	79.5%	17.9%	54.9%	35.1%	56.3%	84.6%	76.0%	14.8%	66.2%	155.1%	91.6%	158.7%	80.5%	40.9%	35.7%	20.3%	38.0%	20.0%	22.0%	61.0%	23.3%	28.2%	65.5%	-20.4%	-23.2%	-11.0%	-3.7%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 30 periods

	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	14.6%	14.2%	19.0%	17.9%	19.3%	21.3%	24.0%	21.8%	22.7%	17.0%	11.1%	5.3%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	5.5%	12.2%	17.7%	24.0%	24.1%	24.5%	22.6%	23.5%	23.3%	25.0%	25.9%
ROCE	22.8%	22.9%	26.6%	25.6%	27.7%	30.9%	32.4%	30.3%	30.8%	31.1%	31.6%	28.2%	28.2%	24.0%	22.3%	22.2%	23.6%	25.1%	28.6%	31.4%	32.9%	32.4%	33.0%	31.9%	32.3%	28.1%	29.2%	29.4%	31.8%	34.3%
Net margin	15.2%	14.1%	17.6%	18.0%	18.9%	20.4%	22.1%	22.6%	22.9%	16.2%	10.3%	5.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.7%	10.0%	14.5%	19.5%	19.6%	19.4%	19.6%	19.5%	19.4%	19.6%	20.2%
EBITDA margin	26.4%	25.7%	27.2%	26.4%	27.9%	30.7%	31.6%	34.6%	33.5%	31.4%	30.4%	27.8%	26.3%	24.0%	21.3%	19.7%	20.6%	22.6%	25.4%	27.4%	28.0%	27.5%	27.4%	27.1%	26.6%	26.1%	26.1%	25.6%	25.4%	27.1%
Debt / equity	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05	0.05	0.05	0.02
Interest coverage	187.13	68.96	66.93	56.75	62.21	97.63	91.81	109.85	113.14	132.78	174.54	90.16	96.18	85.00	66.63	128.61	137.39	121.86	146.07	155.50	165.60	110.69	74.98	58.36	48.43	56.18	66.59	86.52	107.44	132.03
Asset turnover	0.80	0.84	0.90	0.78	0.80	0.82	0.85	0.76	0.79	0.83	0.85	0.82	0.87	0.81	0.84	0.80	0.81	0.88	0.91	0.91	0.93	0.94	0.95	0.93	0.96	0.88	0.92	0.89	0.94	0.97

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 18 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	18	18	18	18	18	18	18	17	17	26	25	25	25	25	25	25	25	25
Other equity / reserves	576	823	1,173	1,486	2,024	2,228	2,581	2,978	3,247	3,578	3,363	3,457	3,542	3,652	3,765	4,290	4,502	4,833
Total equity	593	841	1,191	1,504	2,041	2,245	2,599	2,996	3,264	3,603	3,388	3,482	3,567	3,677	3,790	4,315	4,527	4,858
Borrowings	113	51	61	—	1	34	44	2	2	2	1	1	1	2	3	202	212	104
Current liabilities	275	250	—	212	346	378	606	649	647	705	1,139	799	895	537	996	1,160	1,416	1,343
Non-current liabilities	81	56	—	32	61	73	114	134	144	140	152	152	175	577	229	198	212	224
Total assets	949	1,146	1,488	1,749	2,449	2,696	3,319	3,779	4,056	4,448	4,679	4,433	4,638	4,790	5,015	5,672	6,155	6,425
Property, plant & equipment	277	284	447	567	1,045	1,162	1,360	1,429	1,424	1,397	1,408	1,397	1,384	1,360	1,625	1,740	1,726	1,783
Capital work-in-progress	94	170	238	338	61	262	132	108	153	182	209	205	256	349	176	146	258	327
Investments	63	60	77	199	190	78	79	176	147	306	535	238	349	702	464	874	588	620
Inventories	155	159	205	179	351	436	496	766	791	749	816	786	828	846	904	812	939	967
Receivables	202	259	372	336	460	459	775	738	1,020	1,180	1,057	1,141	1,247	1,016	1,183	1,448	1,854	1,864
Cash & equivalents	60	137	41	19	91	95	202	178	206	329	330	262	129	64	175	90	103	90

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 13 periods

	FY14‡	FY15‡	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	212	279	326	537	281	375	457	576	562	792	785	1,157	529
Cash from investing	-188	-158	-209	-340	-256	-223	-224	-282	-74	-560	65	-377	-429
Cash from financing	-20	-105	-117	-198	-0	-147	-129	-318	-460	-108	-1,051	-733	-168
Capex	—	—	—	—	—	—	—	—	149	174	152	318	365
Free cash flow	—	—	—	—	—	—	—	—	413	617	633	839	164
Dividends paid	15	35	123	114	0	79	113	83	82	90	642	349	350

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹1,783 cr28%

CWIP

₹327 cr5%

Investments

₹620 cr10%

Inventories

₹967 cr15%

Receivables

₹1,864 cr29%

Cash & equivalents

₹90 cr1%

Other assets

₹775 cr12%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Ajanta Pharmaceuticals Ltd.	41,462	3,307.70	32.9	8.53	25.9%

StoxGud checklist: Bullish setup · 9/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-7.3%

6 months+7.4%

1 year+34.4%

3Y CAGR+22.1%

5Y CAGR+17.9%

10Y CAGR+10.0%

50-day avg₹3,461.62

200-day avg₹3,178.69

RSI (14)48

Compare Ajanta Pharmaceuticals Ltd. with

Glaxosmithkline Pharmaceuticals vs Ajanta Pharmaceuticals Emcure Pharmaceuticals vs Ajanta Pharmaceuticals Ajanta Pharmaceuticals vs Narayana Hrudayalaya Ajanta Pharmaceuticals vs Sai Life Sciences Ajanta Pharmaceuticals vs Global Health

FAQs

What is the share price of Ajanta Pharmaceuticals Ltd.?

Ajanta Pharmaceuticals Ltd. (AJANTPHARM) closed at ₹3,307.70 on NSE on 06 Nov 2026.

What is the market cap of Ajanta Pharmaceuticals Ltd.?

₹41,462 crore at the latest close.

What is the P/E ratio of Ajanta Pharmaceuticals Ltd.?

32.9, on trailing-twelve-month earnings from its filings.

How fast is Ajanta Pharmaceuticals Ltd. growing?

Ajanta Pharmaceuticals Ltd.: revenue has compounded at 13.4% a year over three years. Latest-quarter revenue is up 32.5% year on year, profit up 49.2%.

How profitable is Ajanta Pharmaceuticals Ltd.?

On a trailing-twelve-month basis return on equity is 25.9%, return on capital employed 34.3%, operating margin 27.1%, net margin 20.2%.

How much debt does Ajanta Pharmaceuticals Ltd. have?

Ajanta Pharmaceuticals Ltd. is debt-free: debt to equity is 0.02 with borrowings of ₹104 cr against cash of ₹90 cr (balance sheet of 2026-09-30). Operating profit covers interest 132.0 times.

Financials parsed from Ajanta Pharmaceuticals Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.